JP2022533318A5 - - Google Patents
Info
- Publication number
- JP2022533318A5 JP2022533318A5 JP2021564088A JP2021564088A JP2022533318A5 JP 2022533318 A5 JP2022533318 A5 JP 2022533318A5 JP 2021564088 A JP2021564088 A JP 2021564088A JP 2021564088 A JP2021564088 A JP 2021564088A JP 2022533318 A5 JP2022533318 A5 JP 2022533318A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- protein
- amino acid
- domain
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19175413 | 2019-05-20 | ||
| EP19175413.4 | 2019-05-20 | ||
| PCT/EP2020/063973 WO2020234300A1 (en) | 2019-05-20 | 2020-05-19 | A subunit vaccine for treatment or prevention of a respiratory tract infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022533318A JP2022533318A (ja) | 2022-07-22 |
| JP2022533318A5 true JP2022533318A5 (enExample) | 2023-05-31 |
Family
ID=66685352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021564088A Pending JP2022533318A (ja) | 2019-05-20 | 2020-05-19 | 気道感染の治療または予防のためのサブユニットワクチン |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US12162907B2 (enExample) |
| EP (1) | EP3972639A1 (enExample) |
| JP (1) | JP2022533318A (enExample) |
| KR (1) | KR20220010478A (enExample) |
| CN (1) | CN114127101A (enExample) |
| AU (1) | AU2020277661A1 (enExample) |
| BR (1) | BR112021021637A2 (enExample) |
| CA (1) | CA3138064A1 (enExample) |
| CL (1) | CL2021002819A1 (enExample) |
| CO (1) | CO2021014694A2 (enExample) |
| EC (1) | ECSP21079178A (enExample) |
| GB (1) | GB2598494B (enExample) |
| IL (1) | IL287099A (enExample) |
| MX (1) | MX2021013111A (enExample) |
| MY (1) | MY208001A (enExample) |
| PE (1) | PE20220400A1 (enExample) |
| PH (1) | PH12021552736A1 (enExample) |
| SA (1) | SA521430813B1 (enExample) |
| SG (1) | SG11202110646PA (enExample) |
| WO (1) | WO2020234300A1 (enExample) |
| ZA (1) | ZA202106883B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8986704B2 (en) | 2012-07-06 | 2015-03-24 | Valneva Austria Gmbh | Mutant fragments of OspA and methods and uses relating thereto |
| US12018054B2 (en) | 2017-04-13 | 2024-06-25 | Valneva Austria Gmbh | Multivalent OspA polypeptides and methods and uses relating thereto |
| EP3972639A1 (en) | 2019-05-20 | 2022-03-30 | Valneva SE | A subunit vaccine for treatment or prevention of a respiratory tract infection |
| CA3174599A1 (en) | 2020-04-09 | 2021-10-14 | Robert Schlegl | Improvements in vaccine formulations for medical use |
| EP4132950A1 (en) | 2020-04-09 | 2023-02-15 | Valneva Austria GmbH | Compositions comprising three ospa fusion proteins for medical use |
| KR102860080B1 (ko) | 2020-10-09 | 2025-09-15 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 융합전-안정화된 hmpv f 단백질 |
| AU2021380755A1 (en) | 2020-11-13 | 2023-06-22 | Icosavax, Inc. | Protein-based nanoparticle vaccine for metapneumovirus |
| KR20230167017A (ko) | 2021-04-09 | 2023-12-07 | 발네바 에스이 | 인간 메타뉴모 바이러스 백신 |
| US20240335523A1 (en) * | 2021-08-05 | 2024-10-10 | The Regents Of The University Of California | Glycoengineered Foldon Domains and Related Compositions and Methods |
| EP4448802A1 (en) * | 2021-12-16 | 2024-10-23 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion hmpv fusion proteins |
| US20240252614A1 (en) | 2023-01-18 | 2024-08-01 | Pfizer Inc. | Vaccines against respiratory diseases |
| CN121263205A (zh) * | 2023-02-06 | 2026-01-02 | 塞维卡有限责任公司 | 修饰的piv5疫苗载体：制造方法和用途 |
| WO2025126071A1 (en) | 2023-12-14 | 2025-06-19 | Pfizer Inc. | Rna molecules |
| WO2025201243A1 (zh) * | 2024-03-25 | 2025-10-02 | 中国医学科学院医学生物学研究所 | 重组呼吸道合胞病毒融合前f蛋白突变体和其用途 |
| WO2026018181A1 (en) | 2024-07-17 | 2026-01-22 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| CN119176858B (zh) * | 2024-11-22 | 2026-01-09 | 北京华诺泰生物医药科技有限公司 | 一种重组人偏肺病毒融合前f蛋白纯化方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5547871A (en) | 1993-01-25 | 1996-08-20 | American Cyanamid Company | Heterologous signal sequences for secretion of insect controlling proteins |
| EP1167379A3 (en) | 1994-07-15 | 2004-09-08 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| AT408721B (de) | 1999-10-01 | 2002-02-25 | Cistem Biotechnologies Gmbh | Pharmazeutische zusammensetzung enthaltend ein antigen |
| AT409085B (de) | 2000-01-28 | 2002-05-27 | Cistem Biotechnologies Gmbh | Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen |
| RU2413520C2 (ru) | 2000-06-08 | 2011-03-10 | Интерселл Аг | Вакцинная композиция, содержащая иммуностимулирующие олигодезоксинуклеотиды |
| AT410173B (de) | 2000-06-08 | 2003-02-25 | Cistem Biotechnologies Gmbh | Antigene zusammensetzung |
| CA2418854A1 (en) | 2000-08-17 | 2002-02-21 | Jorg Fritz | A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof |
| AT410635B (de) | 2000-10-18 | 2003-06-25 | Cistem Biotechnologies Gmbh | Vakzin-zusammensetzung |
| US8715922B2 (en) * | 2001-01-19 | 2014-05-06 | ViroNovative | Virus causing respiratory tract illness in susceptible mammals |
| WO2002094845A2 (en) | 2001-05-21 | 2002-11-28 | Intercell Ag | Method for stabilising of nucleic acids |
| AU2002358616A1 (en) | 2001-12-07 | 2003-06-17 | Intercell Ag | Immunostimulatory oligodeoxynucleotides |
| DE10221836A1 (de) * | 2002-05-16 | 2003-12-04 | Lohmann Animal Health Gmbh | Attenuierung von Metapneumovirus |
| EP1608402B1 (en) | 2003-03-24 | 2010-10-20 | Intercell AG | Improved vaccines |
| CN101410519B (zh) | 2003-04-25 | 2013-04-24 | 免疫医疗有限责任公司 | 间质肺病毒株及其在疫苗制剂中以及用作抗原性序列表达载体的用途和繁殖病毒的方法 |
| EP2445527A2 (en) | 2009-06-24 | 2012-05-02 | ID Biomedical Corporation of Quebec | Vaccine |
| US20120315270A1 (en) | 2009-10-21 | 2012-12-13 | The United States Of America, As Represented By The | Rsv immunogens, antibodies and compositions thereof |
| CN102145167A (zh) * | 2010-02-05 | 2011-08-10 | 重庆医科大学附属儿童医院 | 重组人类偏肺病毒疫苗 |
| CA2798739A1 (en) | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Nanocarrier compositions with uncoupled adjuvant |
| EP3269386B1 (en) | 2011-12-06 | 2022-09-14 | Valneva Austria GmbH | Aluminium compounds for use in therapeutics and vaccines |
| CN105408348B (zh) * | 2013-06-17 | 2021-07-06 | 扬森疫苗与预防公司 | 稳定化的可溶性融合前rsv f多肽 |
| CL2013002829A1 (es) | 2013-10-01 | 2014-04-04 | Univ Pontificia Catolica Chile | Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv. |
| WO2016103238A1 (en) | 2014-12-24 | 2016-06-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant metapneumovirus f proteins and their use |
| CA2996762A1 (en) * | 2015-08-31 | 2017-03-09 | Technovax, Inc. | Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine |
| EP4011451A1 (en) | 2015-10-22 | 2022-06-15 | ModernaTX, Inc. | Metapneumovirus mrna vaccines |
| US10961283B2 (en) | 2016-06-27 | 2021-03-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens |
| WO2019092002A1 (en) * | 2017-11-07 | 2019-05-16 | Valneva Se | Pharmaceutical compositions for treatment or prevention of viral infections |
| EP3972639A1 (en) | 2019-05-20 | 2022-03-30 | Valneva SE | A subunit vaccine for treatment or prevention of a respiratory tract infection |
| KR20230167017A (ko) | 2021-04-09 | 2023-12-07 | 발네바 에스이 | 인간 메타뉴모 바이러스 백신 |
-
2020
- 2020-05-19 EP EP20726137.1A patent/EP3972639A1/en active Pending
- 2020-05-19 BR BR112021021637A patent/BR112021021637A2/pt unknown
- 2020-05-19 PE PE2021001766A patent/PE20220400A1/es unknown
- 2020-05-19 PH PH1/2021/552736A patent/PH12021552736A1/en unknown
- 2020-05-19 MX MX2021013111A patent/MX2021013111A/es unknown
- 2020-05-19 AU AU2020277661A patent/AU2020277661A1/en active Pending
- 2020-05-19 MY MYPI2021005570A patent/MY208001A/en unknown
- 2020-05-19 CA CA3138064A patent/CA3138064A1/en active Pending
- 2020-05-19 KR KR1020217034461A patent/KR20220010478A/ko not_active Ceased
- 2020-05-19 JP JP2021564088A patent/JP2022533318A/ja active Pending
- 2020-05-19 GB GB2114836.6A patent/GB2598494B/en active Active
- 2020-05-19 US US17/606,811 patent/US12162907B2/en active Active
- 2020-05-19 SG SG11202110646PA patent/SG11202110646PA/en unknown
- 2020-05-19 CN CN202080030901.9A patent/CN114127101A/zh active Pending
- 2020-05-19 WO PCT/EP2020/063973 patent/WO2020234300A1/en not_active Ceased
-
2021
- 2021-09-17 ZA ZA2021/06883A patent/ZA202106883B/en unknown
- 2021-10-07 IL IL287099A patent/IL287099A/en unknown
- 2021-10-25 EC ECSENADI202179178A patent/ECSP21079178A/es unknown
- 2021-10-26 CL CL2021002819A patent/CL2021002819A1/es unknown
- 2021-10-29 CO CONC2021/0014694A patent/CO2021014694A2/es unknown
- 2021-11-10 SA SA521430813A patent/SA521430813B1/ar unknown
-
2023
- 2023-10-24 US US18/493,004 patent/US12162909B2/en active Active
-
2024
- 2024-10-31 US US18/932,700 patent/US20250171501A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022533318A5 (enExample) | ||
| GB2598494A (en) | A subunit vaccine for treatment or prevention of a respiratory tract infection | |
| US11229694B2 (en) | Vaccine against RSV | |
| EP0276014B1 (en) | Anticoagulant peptides | |
| JP2024522385A5 (enExample) | ||
| JP2015512876A5 (enExample) | ||
| JP2025184979A5 (enExample) | ||
| JP2024102211A5 (enExample) | ||
| JP2023544834A5 (enExample) | ||
| JP2020203894A5 (enExample) | ||
| JP2021523878A5 (enExample) | ||
| NO20025153D0 (no) | FremgangsmÕter og sammensetninger for Õ svekke formering av HIV-1 | |
| JP2011518179A5 (enExample) | ||
| JP2023514452A5 (enExample) | ||
| JP2024508683A5 (enExample) | ||
| JP2020515283A5 (enExample) | ||
| HUP0103784A2 (hu) | MUC-1-et kódoló DNS molekulák és ezek alkalmazása tumorellenes vakcinálásban | |
| RU2021128047A (ru) | Субъединичная вакцина для лечения или предотвращения инфекции дыхательных путей | |
| JP2024504136A5 (enExample) | ||
| HK40051815A (en) | Vaccine against rsv comprising modified f polypeptide | |
| ZA202400920B (en) | Recombinant antigen for inducing an immune response against the zika virus | |
| RU2024104848A (ru) | Рекомбинантный антиген для индукции иммунного ответа против вируса зика | |
| JP2022547335A5 (enExample) | ||
| JPWO2021112235A5 (enExample) | ||
| HK1250939B (en) | Vaccine against rsv |